Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy.
Publications
View AllThe landscape of cancer genes and mutational processes in breast cancer
All cancers carry somatic mutations in their genomes. A subset, known as driver mutations, confer clonal selective advantage on cancer cells and are causally implicated in oncog...
Affiliated Researchers
Institution Info
- Type
- healthcare
- Country
- SG
- Publications
- 2
- Citations
- 7,125
External Links
Identifiers
- ROR
- https://ror.org/03bqk3e80